"I remain impressed with the Anadys team and optimistic about the projects," said Dr. Fritz. "Steve Worland is an extremely capable individual who has all the skills to lead the Company forward, and I wish him and the Company all the best."
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by developing and commercializing novel small molecule medicines for the treatment of hepatitis C virus (HCV) infection and cancer. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5b polymerase for the treatment of HCV and ANA773, an oral TLR7 agonist prodrug for cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements include,
but are not limited to, references to the expected timing and planned
development activities for ANA598 and ANA773. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors, which may cause Anadys' actual results to be materially different
from historical results or from any results expressed or implied by such
forward-looking statements. For example, the results of in vitro studies
and initial clinical trials may not be predictive of future results, and
Anadys cannot provide any assurances that any of its product candidates
will not have unforeseen safety issues, will have favorable results in
future clinical trials or will receive regulatory approval. In addition,
Anadys' results may be affected by risks related to its agreements with
Novartis and LG Life Sciences, competition from other biotechnology and
pharmaceutical companies, its effectiveness at managing its finan
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved